#USA #New York #TSC Alliance #Apertura Gene Therapy #Tuberous Sclerosis

Advancements in Gene Therapy for Tuberous Sclerosis Complex

In a significant development for the treatment of tuberous sclerosis complex (TSC), the TSC Alliance, a renowned nonprofit organization, has completed a preclinical pilot study in collaboration with Apertura Gene Therapy. This groundbreaking study focused on an adeno-associated virus (AAV) gene therapy aimed at addressing the TSC1 gene. The collaboration signals a commitment to exploring innovative therapies to enhance the quality of life for individuals affected by this rare genetic disorder.

The preclinical study employed Apertura's novel TfR1 CapX™ capsid to deliver gene therapies effectively across the blood-brain barrier (BBB). This particular capsid is designed to interact with human transferrin receptor 1 (hTfR1), facilitating intravenous delivery to crucial neurological and organ systems. Conducting preliminary trials with promising results, the organizations are encouraged by the findings that will guide future testing and the eventual leap into clinical trials.

Dr. Dean Aguiar, Executive Vice President of Translational Research at TSC Alliance, expressed optimism about the study results. He indicated that these initial findings support the continued preclinical evaluation of the TSC1 gene therapy approach and the potential opening for clinical applications. To push the research forward, the TSC Alliance has pledged to raise $1.76 million over the coming year and a half, specifically targeting gene therapy studies to understand better the efficacy for TSC1 and TSC2.

This financial commitment underscores the Alliance's long-term dedication to advancing research into effective treatments for TSC, a genetic condition characterized by non-cancerous tumor formation across various organs, notably the brain. An alarming statistic from the TSC community reveals that about 85% of individuals with TSC experience seizures, complicating their health condition, with a significant portion facing refractory epilepsy. The ongoing research aims to improve these patients' therapeutic options significantly.

The TSC Alliance has a storied history of fundraising to bolster TSC research and remains committed to working closely with the community it serves. As Kari Luther Rosbeck, the Alliance's President and CEO noted, the pathway to advancing gene therapy could profoundly impact countless individuals living with TSC. This collaboration with Apertura Gene Therapy, which has a keen focus on patient-centered drug development, is indeed a step toward that goal.

The TfR1 CapX™ capsid offers more than just a pathway for effective gene delivery; it has shown superior capabilities in delivering genetic material across the BBB compared to its predecessors. The validation and licensing of TfR1 CapX™ by multiple entities reflect a robust foundation of support, indicating a strong interest in advancing the underlying technology to clinical readiness. With several preclinical development programs underway, the efforts to engage with regulatory bodies signify a proactive approach to the challenges that such innovative therapies usually encounter.

The TSC Alliance is poised to share its insights and updates regarding gene therapy at the upcoming 2026 TSC World Conference in Aurora, Colorado, aimed at advocating the potential of such research and gathering community support for continued exploration.

As gene therapies continue to evolve, the collaboration between the TSC Alliance and Apertura Gene Therapy illuminates a promising future not just for research innovation but for the hope it brings to patients and families dealing with the impacts of TSC. With ongoing support and innovative technology, the dream of providing effective treatments and, eventually, a cure for tuberous sclerosis complex becomes increasingly attainable.